Veracyte investor relations material
Listen to the latest call from Veracyte
Veracyte, Inc. develops and commercializes blood tests for the early detection of lung cancer and emphysema. The company offers Veracyte Drug Screening Assay and Veracyte Acute Exacerbation Panel (V-AEP) for the detection of Lung Cancer and Chronic Obstructive Pulmonary Disease (COPD). Its drug screening assays are based on a proprietary approach of analyzing patient genomic data to predict which patients are most likely to have cancer after receiving a lung CT scan. The company markets its products through direct sales force, as well as through clinical laboratory partners, medical practitioners, and directly to patients.